Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Treasury Shares (2016 - 2025)

Orthofix Medical has reported Treasury Shares over the past 16 years, most recently at $2.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares rose 57.14% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, up 57.14%, and an annual FY2025 reading of $2.2 million, up 57.14% over the prior year.
  • Treasury Shares came in at $2.2 million for Q4 2025, up from $1.4 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.2 million in Q4 2025 to a low of $3686.0 in Q4 2022.
  • Median Treasury Shares over the past 5 years was $200000.0 (2023), compared with a mean of $762211.6.
  • The sharpest move saw Treasury Shares tumbled 98.94% in 2021, then soared 5325.94% in 2023.
  • Over 5 years, Treasury Shares stood at $7372.0 in 2021, then plummeted by 50.0% to $3686.0 in 2022, then soared by 5325.94% to $200000.0 in 2023, then surged by 600.0% to $1.4 million in 2024, then skyrocketed by 57.14% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for OFIX's Treasury Shares are $2.2 million (Q4 2025), $1.4 million (Q4 2024), and $200000.0 (Q4 2023).